Possible role of PPAR-γ and COX-2 receptor modulators in the treatment of Non-Small Cell lung carcinoma

Med Hypotheses. 2019 Mar:124:98-100. doi: 10.1016/j.mehy.2019.02.024. Epub 2019 Feb 4.

Abstract

Non-Small Cell lung cancer (NSCLC) accounts for 85% of total lung cancers worldwide, affecting more than 1.5 million people every year. Recent studies reported that lung adenocarcinoma express Peroxisome Proliferator Activated Receptor-γ (PPAR-γ) which is believed to be inactivated due to cytoplasmic accumulation or somatic 'loss of function' of the gene. PPAR-γ reported to play an important role in cell proliferation, cell differentiation and apoptosis via inhibition of NF-kβ pathway. Adenocarcinoma also overexpress cyclooxygenase-2 (COX-2), which is reported to promote angiogenesis and metastasis via TX-A2 production. Therefore, we hypothesize that activation of PPAR-γ (through PPAR-γ agonists) and inhibition of COX-2 (through COX-2 inhibitors) will have beneficial effects in the treatment of NSCLC.

Keywords: COX-2; Lung cancer; Metastasis; NSCLC; PPAR-γ.

MeSH terms

  • Adenocarcinoma / metabolism
  • Adenocarcinoma / therapy
  • Animals
  • Apoptosis
  • Carcinoma, Non-Small-Cell Lung / metabolism*
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Cell Differentiation
  • Cell Division
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cyclooxygenase 2 / metabolism*
  • Cyclooxygenase 2 Inhibitors / pharmacology
  • Humans
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / therapy*
  • MAP Kinase Signaling System
  • Neoplasm Metastasis
  • Neovascularization, Pathologic
  • PPAR gamma / metabolism*
  • Transcription Factors / genetics

Substances

  • Cyclooxygenase 2 Inhibitors
  • PPAR gamma
  • Transcription Factors
  • Cyclooxygenase 2